Recursion Pharmaceuticals has received a consensus rating of "Hold" from six analysts covering the company, with individual opinions ranging from one "Sell" through three "Hold" to two "Buy" recommendations. Over the past year, these analysts have established an average 12-month price target of $9.40, reflecting a narrow range of expectations despite Recursion’s evolving clinical pipeline and AI-driven platform progress.

On December 17, JPMorgan Chase & Co. upgraded Recursion from "Neutral" to "Overweight" and raised its own target to $11.00, citing advancing proof-of-concept data from the company’s lead program. On the same day, Morgan Stanley and UBS Group each reiterated buy views with $11.00 targets. Conversely, Weiss Ratings maintained a "Sell (D-)" stance as of October 8, underscoring concerns over cash burn rates and the timing of clinical readouts.

Director Blake Borgeson sold 220,000 shares on January 6 at an average of $4.36 per share, reducing his stake by 3.2% and realizing approximately $959,200. CFO Ben R. Taylor offloaded 21,383 shares on December 29 at an average of $4.18, a 2.7% ownership reduction valued at $89,380. Over the past 90 days, insiders have sold 585,786 shares, totaling $2.56 million in proceeds and representing 8.43% of the company’s shares.

UBS Asset Management Americas boosted its stake by 183.7% in Q1, acquiring 4.15 million additional shares to reach 6.41 million shares valued at $33.9 million. Norges Bank initiated a $16.0 million position in Q2, while Bank Pictet & Cie Europe added roughly $7.95 million in Q3. Stratos Wealth Partners expanded its holding by 724.3% to 98,704 shares ($499,000) in Q2, and Ethic Inc. entered with a $107,000 stake. Institutional ownership now stands at approximately 89.1%.